← Product Code [LZA](/submissions/HO/subpart-g%E2%80%94general-hospital-and-personal-use-miscellaneous-devices/LZA) · K102074 # POWDER FREE NITRILE EXAMINATION GLOVES, TESTED FOR USE WITH CHEMOTHERAPY DRUGS, BLUE (SG) (K102074) _Gx Corporation Sdn Bhd · LZA · Nov 2, 2010 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-g%E2%80%94general-hospital-and-personal-use-miscellaneous-devices/LZA/K102074 ## Device Facts - **Applicant:** Gx Corporation Sdn Bhd - **Product Code:** [LZA](/submissions/HO/subpart-g%E2%80%94general-hospital-and-personal-use-miscellaneous-devices/LZA.md) - **Decision Date:** Nov 2, 2010 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.6250 - **Device Class:** Class 1 - **Review Panel:** General Hospital ## Indications for Use This glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. This glove has been tested for use with specific chemotherapy drugs listed below. ## Device Story Disposable nitrile examination glove; worn by healthcare examiners to prevent cross-contamination between patient and examiner. Device provides barrier protection during medical procedures and handling of specific chemotherapy drugs. Tested for permeation breakthrough times against various chemotherapy agents; results provided for clinical awareness regarding exposure risks (e.g., Carmustine and Thio-Tepa show low breakthrough times). Used in clinical settings; operated by healthcare professionals. ## Clinical Evidence Bench testing only. Permeation testing performed for specific chemotherapy drugs; breakthrough detection times reported in minutes for 14 agents. ## Technological Characteristics Nitrile material; powder-free; blue color; disposable; examination glove form factor. Tested for chemotherapy drug permeation resistance. ## Regulatory Identification A non-powdered patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. A non-powdered patient examination glove does not incorporate powder for purposes other than manufacturing. The final finished glove includes only residual powder from manufacturing. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract shapes resembling waves or stylized human figures. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Mr. Cho S. Fong Quality Assurance/ Regulatory Affairs Manager GX Corporation SDN BHD Lot 6487A, Batu 53/4, Sementa, Jalan Kapar Klang, Selangdor Darul Ehsan, Malaysia 42100 NOV - 2 2010 Re: K102074 Trade/Device Name: Powder Free Nitrile Examination Gloves, Tested For Use With Chemotherapy Drugs, Blue (SG) Regulation Number: 21 CFR 880.6250 Regulation Name: Patient Examination Glove Regulatory Class: I Product Code: LZA Dated: September 29, 2010 Received: October 4, 2010 . Dear Mr. Fong: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Page 2- Mr. Fong Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. · Sincerely vours. Wh for Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use | 510(k)-Number (if known): | K102074 | NOV - 2 2010 | |---------------------------|-----------------------------------------------------------------------------------------------|--------------| | Device Name: | Powder Free Nitrile Examination Gloves,
Tested For Use With Chemotherapy Drugs, Blue (SG). | | **Indication For Use:** This glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. This glove has been tested for use with specific chemotherapy drugs listed below. **Chemotherapy Drug Permeation (Breakthrough Detection Time in Minutes)** | Dacarbazine (DTIC) (10.0 mg/mL) | > 240 | |-----------------------------------------|-------| | Mitomycin C (5.0 mg/mL) | > 240 | | Carmustine (BCNU) (3.3 mg/mL) | 3.48 | | Cyclophosphamide (Cytoxan) (20.0 mg/mL) | > 240 | | Doxorubicin Hydrochloride (2.0 mg/mL) | > 240 | | 5-Fluorouracil (50.0 mg/mL) | > 240 | | Cisplatin (1.0 mg/mL) | > 240 | | Etoposide (20.0 mg/mL) | > 240 | | Paclitaxel (taxol) (6.0 mg/mL) | > 240 | | Thio-Tepa (10.0 mg/mL) | 2.97 | | Vincristine Sulfate (50.0 mg/mL) | > 240 | | Methotrexate (25.0 mg/mL) | > 240 | | Mitoxantrone (100.0 mg/mL) | > 240 | | Ifosfamide (Ifex) (50.0 mg/mL) | > 240 | Please note that the following drugs; Carmustine and Thio-Tepa have extremely low permeation time of 3.48 and 2.97 minutes. | Prescription Use _______
(Part 21 CFR 801 Subpart D) | AND/OR | Over-The-Counter Use _______ X
(21 CFR 801 Subpart C) | |---------------------------------------------------------|--------|----------------------------------------------------------| |---------------------------------------------------------|--------|----------------------------------------------------------| (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office Of Device Evaluation (ODE) h (Division Sign-Off) (Division Sign-Off) Division of Anesthesiology, General Hospital Clivision of Anesthesiology, General Devices Division of Anesthoolors of Infection Control, Devices 510(k) Number: K102074 Page 1 of --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-g%E2%80%94general-hospital-and-personal-use-miscellaneous-devices/LZA/K102074](https://fda.innolitics.com/submissions/HO/subpart-g%E2%80%94general-hospital-and-personal-use-miscellaneous-devices/LZA/K102074) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com